Yang Liu

机构：Shenyang Pharmaceutical University, Fujian University of Traditional Chinese Medicine, Fujian Medical University, Zunyi Medical University, Chinese PLA General Hospital, Revolution Medicines (United States), Beijing Chest Hospital, Veracyte (United States) · ORCID：0000-0002-1871-6889

发表论文 70 篇 · 总被引 1726 次 · h-index 24

代表论文

• Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers (2025 · Journal of Medicinal Chemistry · 被引 92)
• The role of ubiquitination in health and disease (2024 · MedComm · 被引 53)
• Discovery of Elironrasib (RMC-6291), a Potent and Orally Bioavailable, RAS(ON) G12C-Selective, Covalent Tricomplex Inhibitor for the Treatment of Patients with RAS G12C-Addicted Cancers (2025 · Journal of Medicinal Chemistry · 被引 49)
• A microprotein N1DARP encoded by LINC00261 promotes Notch1 intracellular domain (N1ICD) degradation via disrupting USP10-N1ICD interaction to inhibit chemoresistance in Notch1-hyperactivated pancreatic cancer (2023 · Cell Discovery · 被引 47)
• The proteasome component PSMD14 drives myelomagenesis through a histone deubiquitinase activity (2023 · Molecular Cell · 被引 38)
• Discovery of X10g as a selective PROTAC degrader of Hsp90α protein for treating breast cancer (2023 · European Journal of Medicinal Chemistry · 被引 15)